$ 36.4
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Favourable price performance
About
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is overpriced on P/FCF.
Target Price
The average target price of NAMS is 44 and suggests 21% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
